Skip to main content

Table1 Correlation between NEK2 expression and clinicopathological parameters

From: NEK2 promotes the migration and proliferation of ESCC via stabilization of YAP1 by phosphorylation at Thr-143

  Higher expression of NEK2 (n = 57) Lower expression of NEK2 (n = 46) P
Sex, Male (%) 49 (86.0) 36 (78.3) 0.446
Age (mean (SD)) 66.61 (9.47) 64.61 (7.40) 0.243
Size (mean (SD)) 4.70 (1.79) 4.83 (1.77) 0.717
Location (%)    0.779
 Middle 46 (80.7) 39 (84.8)  
 Others 10 (19.3) 8 (15.2)  
Morphology (%)    0.111
 Plaque 11 (19.3) 5 (10.9)  
 Fungoid 12 (21.1) 14 (30.4)  
 Ulcerative 0 (0.0) 3 (6.5)  
 Medullary 34 (59.6) 24 (52.2)  
Grade (%)    0.001
 G1 2 (3.5) 13 (28.3)  
 G2 40 (70.2) 28 (60.9)  
 G3 15 (26.3) 5 (10.8)  
Invasion depth (%)    0.557
 Submucosal 1 (1.8) 2 (4.3)  
 Muscular 14 (24.6) 14 (30.4)  
 Serosa 42 (73.7) 30 (65.2)  
Lymph node metastasis    0.029
 Yes 34 (59.6) 17 (37.0)  
 No 23 (40.4) 29 (63.0)  
T stage (%)    0.462
 T1 1 (1.8) 2 (4.3)  
 T2 13 (22.8) 13 (28.3)  
 T3 41 (71.9) 31 (67.4)  
 T4 2 (3.5) 0 (0.0)  
N stage (%)    0.065
 N0 23 (40.4) 29 (63.0)  
 N1 20 (35.1) 11 (23.9)  
 N2 10 (17.5) 6 (13.0)  
 N3 4 (7.0) 0 (0.0)  
Metastasis 0 0  
AJCC* stage (%)    0.001
 I 1 (1.8) 5 (10.9)  
 II 22 (38.6) 24 (52.2)  
 III 27 (47.4) 17 (37.0)  
 IV 7 (12.3) 0 (0.0)  
  1. *AJCC The 8th Version of American Joint Committee on Cancer